Thrombus formation can lead to heart attacks, stroke and pulmonary embolism, which are major causes of mortality. Current standard diagnostic imaging methods detect anatomic abnormalities such as vascular flow impairment but have limitations. By using a targeted molecular imaging approach critical components of a pathology can be selectively visualized and exploited for an improved diagnosis and patient management. The GPIIb/IIIa receptor is abundantly and specifically exposed on activated platelets and is the key receptor in thrombus formation. This commentary describes the current status of GPIIb/IIIa-based PET imaging approaches with a focus on the recently published preclinical data of the small-molecule PET tracer 18F-GP1. Areas of future research and potential clinical applications are discussed that may lead to an improved detection of critical thromboembolic events and an optimization of available antithrombotic therapies by tracking activated platelets.

中文翻译：

---

18F-GP1的评论，这是一种新颖的PET示踪剂，专为高灵敏度，低背景血栓检测设计：对血凝块中的活化血小板进行成像-我们到那里了吗？

血栓形成可导致心脏病，中风和肺栓塞，这是造成死亡的主要原因。当前的标准诊断成像方法可检测解剖异常，例如血管流量障碍，但有局限性。通过使用靶向分子成像方法，可以选择性地可视化和利用病理学的关键组成部分，以改善诊断和患者管理。GPIIb / IIIa受体大量且特异性地暴露在活化的血小板上，是血栓形成中的关键受体。这篇评论描述了基于GPIIb / IIIa的PET成像方法的当前状态，重点是小分子PET示踪剂18F-GP1的最新临床前数据。